Friday, November 08, 2019 2:21:43 PM
Celgene Corp. (CELG) and Acceleron are jointly developing Reblozyl, the companies said.
At 12:55 p.m. EST, Acceleron shares had gained 6.01%, to trade at $43.05.
Celgene shares were up 0.35%, to $109.38, following the news.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2019 13:00 ET (18:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
New York Yankees and Duke Basketball
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM